Cargando…

FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1

F-box and WD repeat domain-containing 7 (FBW7) has been characterized as a tumor suppressor, and its mutation or decreased expression has been observed in many types of human cancers. Our recent studies have uncovered that in pancreatic cancer, the KRAS mutation decreased FBW7 expression through pho...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Qiangsheng, Qin, Yi, Zhang, Bo, Liang, Chen, Ji, Shunrong, Shi, Si, Xu, Wenyan, Xiang, Jinfeng, Liang, Dingkong, Ni, Quanxing, Yu, Xianjun, Xu, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652962/
https://www.ncbi.nlm.nih.gov/pubmed/28765935
http://dx.doi.org/10.3892/or.2017.5856
_version_ 1783273161596338176
author Hu, Qiangsheng
Qin, Yi
Zhang, Bo
Liang, Chen
Ji, Shunrong
Shi, Si
Xu, Wenyan
Xiang, Jinfeng
Liang, Dingkong
Ni, Quanxing
Yu, Xianjun
Xu, Jin
author_facet Hu, Qiangsheng
Qin, Yi
Zhang, Bo
Liang, Chen
Ji, Shunrong
Shi, Si
Xu, Wenyan
Xiang, Jinfeng
Liang, Dingkong
Ni, Quanxing
Yu, Xianjun
Xu, Jin
author_sort Hu, Qiangsheng
collection PubMed
description F-box and WD repeat domain-containing 7 (FBW7) has been characterized as a tumor suppressor, and its mutation or decreased expression has been observed in many types of human cancers. Our recent studies have uncovered that in pancreatic cancer, the KRAS mutation decreased FBW7 expression through phosphorylation and subsequent ubiquitination. Moreover, FBW7 inhibited aerobic glycolysis in pancreatic cancer via induction of thioredoxin-interacting protein (TXNIP), a mitochondrial localized tumor suppressor. The roles of FBW7 in anti-apoptosis and drug resistance via proteosomal degradation of myeloid cell leukemia-1 (MCL-1), which is an anti-apoptotic factor have been reported. However, the role of FBW7 in the chemotherapeutic resistance of pancreatic cancer to gemcitabine has seldom been reported. In the present study, we demonstrated that overexpression of FBW7 in pancreatic cancer cells rendered increased sensitivity to gemcitabine. Mechanistically, FBW7 promoted gemcitabine sensitivity via upregulation of equilibrative nucleoside transporter 1 (ENT1) at the protein level rather than the transcriptional level. In depth analysis demonstrated that the ENT1 protein level could be increased by lysosome inhibition. Taken together, our results demonstrated that FBW7 could be a target for improving the therapeutic efficacy of gemcitabine by induction of ENT1.
format Online
Article
Text
id pubmed-5652962
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-56529622017-11-02 FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1 Hu, Qiangsheng Qin, Yi Zhang, Bo Liang, Chen Ji, Shunrong Shi, Si Xu, Wenyan Xiang, Jinfeng Liang, Dingkong Ni, Quanxing Yu, Xianjun Xu, Jin Oncol Rep Articles F-box and WD repeat domain-containing 7 (FBW7) has been characterized as a tumor suppressor, and its mutation or decreased expression has been observed in many types of human cancers. Our recent studies have uncovered that in pancreatic cancer, the KRAS mutation decreased FBW7 expression through phosphorylation and subsequent ubiquitination. Moreover, FBW7 inhibited aerobic glycolysis in pancreatic cancer via induction of thioredoxin-interacting protein (TXNIP), a mitochondrial localized tumor suppressor. The roles of FBW7 in anti-apoptosis and drug resistance via proteosomal degradation of myeloid cell leukemia-1 (MCL-1), which is an anti-apoptotic factor have been reported. However, the role of FBW7 in the chemotherapeutic resistance of pancreatic cancer to gemcitabine has seldom been reported. In the present study, we demonstrated that overexpression of FBW7 in pancreatic cancer cells rendered increased sensitivity to gemcitabine. Mechanistically, FBW7 promoted gemcitabine sensitivity via upregulation of equilibrative nucleoside transporter 1 (ENT1) at the protein level rather than the transcriptional level. In depth analysis demonstrated that the ENT1 protein level could be increased by lysosome inhibition. Taken together, our results demonstrated that FBW7 could be a target for improving the therapeutic efficacy of gemcitabine by induction of ENT1. D.A. Spandidos 2017-10 2017-07-28 /pmc/articles/PMC5652962/ /pubmed/28765935 http://dx.doi.org/10.3892/or.2017.5856 Text en Copyright: © Hu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Hu, Qiangsheng
Qin, Yi
Zhang, Bo
Liang, Chen
Ji, Shunrong
Shi, Si
Xu, Wenyan
Xiang, Jinfeng
Liang, Dingkong
Ni, Quanxing
Yu, Xianjun
Xu, Jin
FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1
title FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1
title_full FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1
title_fullStr FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1
title_full_unstemmed FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1
title_short FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1
title_sort fbw7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ent1
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652962/
https://www.ncbi.nlm.nih.gov/pubmed/28765935
http://dx.doi.org/10.3892/or.2017.5856
work_keys_str_mv AT huqiangsheng fbw7increasesthechemosensitivityofpancreaticcancercellstogemcitabinethroughupregulationofent1
AT qinyi fbw7increasesthechemosensitivityofpancreaticcancercellstogemcitabinethroughupregulationofent1
AT zhangbo fbw7increasesthechemosensitivityofpancreaticcancercellstogemcitabinethroughupregulationofent1
AT liangchen fbw7increasesthechemosensitivityofpancreaticcancercellstogemcitabinethroughupregulationofent1
AT jishunrong fbw7increasesthechemosensitivityofpancreaticcancercellstogemcitabinethroughupregulationofent1
AT shisi fbw7increasesthechemosensitivityofpancreaticcancercellstogemcitabinethroughupregulationofent1
AT xuwenyan fbw7increasesthechemosensitivityofpancreaticcancercellstogemcitabinethroughupregulationofent1
AT xiangjinfeng fbw7increasesthechemosensitivityofpancreaticcancercellstogemcitabinethroughupregulationofent1
AT liangdingkong fbw7increasesthechemosensitivityofpancreaticcancercellstogemcitabinethroughupregulationofent1
AT niquanxing fbw7increasesthechemosensitivityofpancreaticcancercellstogemcitabinethroughupregulationofent1
AT yuxianjun fbw7increasesthechemosensitivityofpancreaticcancercellstogemcitabinethroughupregulationofent1
AT xujin fbw7increasesthechemosensitivityofpancreaticcancercellstogemcitabinethroughupregulationofent1